Biomarkers of Cartilage and Surrounding Joint Tissue

Abstract

The identification and clinical demonstration of efficacy and safety of osteo- and chondro-protective drugs are met with certain difficulties. During the last few decades, the pharmaceutical industry has, in the field of rheumatology, experienced disappointments associated with the development of disease modification. Today, the vast amount of patients suffering from serious, chronic joint diseases can only be offered treatments aimed at improving symptoms, such as pain and acute inflammation, and are not aimed at protecting the joint tissue. This huge, unmet medical need has been the driver behind the development of improved analytical techniques allowing better and more efficient clinical trial design, implementation and analysis. With this review, we aim to provide a brief and general overview of biochemical markers of joint tissue, with special focus on neoepitopes. Furthermore, we highlight recent studies applying biochemical markers in joint degenerative diseases. These disorders, including osteoarthritis, rheumatoid arthritis and spondyloarthropathies, are the most predominant disorders in Europe and the USA, and have enormous socioeconomical impact.

Collagen biology and non‐invasive biomarkers of liver fibrosis

“…Some of the most common technical, analytical and clinical parameters known to influence evaluation and validation of novel serological biomarkers are outlined in Table . Several of these parameters and the context in which the results are interpreted are often underestimated, but can have a significant impact on the final interpretation of results . Technical performance is especially critical for reproducible and reliable biomarker analyses.…”

“…64 Several of these parameters and the context in which the results are interpreted are often underestimated, but can have a significant impact on the final interpretation of results. 65…”

Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients

“…The end stage of joint failure is TJR. No serologic profile exists for prediction or coincident detection of TJR that could guide more objective decisions and provide further insights into pathways and biological processes leading to TJR 8,9 . If upregulated biological processes are predictive and diagnostic for TJR, interventions that attenuate these processes and delay TJR may be identified.…”

Osteochondral repair using an acellular dermal matrix—pilot in vivo study in a rabbit osteochondral defect model

“…Image analysis of immunohistochemistry provided key information regarding the quality and quantity extent of defect repair. Type II collagen expression is considered a marker of chondrocytic activity . The proportion of type II collagen was considered a surrogate marker for hyaline cartilage, and therefore a marker for the quality of the repair.…”